Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
lyra therapeutics股票：分析師視角深度探討（4項評級）
In the latest quarter, 4 analysts provided ratings for Lyra Therapeutics (NASDAQ:LYRA), showcasing a mix of bullish and bearish perspectives.
在最新的季度中，有4位分析師爲純度生物療法（納斯達克：LYRA）提供了評級，展示了看好和看淡的觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.38, with a high estimate of $12.00 and a low estimate of $0.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 43.69%.
分析師對12個月價格目標的評估提供了額外的洞察力，顯示平均目標爲6.38美元，最高估值爲12.00美元，最低估值爲0.50美元。隨着分析師將平均價格目標下調了43.69％，情緒出現了負向轉移。
Decoding Analyst Ratings: A Detailed Look
分析師評級解讀：詳細解析
An in-depth analysis of recent analyst actions unveils how financial experts...
對最近分析師活動的深入分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。